<SEC-DOCUMENT>0001144204-18-001813.txt : 20180111
<SEC-HEADER>0001144204-18-001813.hdr.sgml : 20180111
<ACCEPTANCE-DATETIME>20180111083114
ACCESSION NUMBER:		0001144204-18-001813
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20180111
DATE AS OF CHANGE:		20180111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AmpliPhi Biosciences Corp
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-210974
		FILM NUMBER:		18522746

	BUSINESS ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		804-827-2524

	MAIL ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tv483099_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Arial Narrow, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #DE1A1E"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B><BR>
<B>File No. 333-210974</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #DE1A1E"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To Prospectus dated May 13, 2016) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.3pt"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 14pt"><B>4,000,000
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.5pt; text-align: center">&nbsp;<IMG SRC="tv483099_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering 4,000,000 shares of our
common stock pursuant to this prospectus supplement and the accompanying prospectus.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is traded on the NYSE American
under the symbol &ldquo;APHB.&rdquo; On January 9, 2018, the last reported sale price of our common stock as reported on the NYSE
American was $1.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 9pt">We have retained
H.C. Wainwright &amp; Co., LLC to act as our exclusive placement agent (&ldquo;placement agent&rdquo;) in connection with the
shares of common stock offered by this prospectus supplement. The placement agent has agreed to use its reasonable best efforts
to arrange for the sale of the common stock offered by this prospectus supplement. The placement agent is not purchasing or selling
any of the shares of common stock we are offering and the placement agent is not required to arrange the purchase or sale of any
specific number of shares or dollar amount. We have agreed to pay to the placement agent the placement agent fees set forth in
the table below, which assumes that we sell all of the common stock offered by this prospectus supplement. See &ldquo;Plan of
Distribution&rdquo; on page S-12 of this prospectus supplement for more information regarding these arrangements.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 9pt">As of the
date of this prospectus supplement, the aggregate market value of our outstanding common stock held by non-affiliates, or public
float, was approximately $17.3 million, based on 9,271,504 shares of outstanding common stock held by non-affiliates as of the
date of this prospectus supplement, at a price of $1.87 per share, which was the last reported sale price of our common stock
on the NYSE&nbsp;American on January 8, 2018. Pursuant to General Instruction I.B.6 of Form&nbsp;S-3, in no event will we sell
securities registered on the registration statement of which this prospectus supplement is a part in a primary offering with a
value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0
million. Other than the securities offered by this prospectus supplement, we have not offered any securities pursuant to General
Instruction I.B.6 of Form&nbsp;S-3 during the 12 calendar months prior to and including the date of this prospectus supplement.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our common stock involves
a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-5 of this prospectus supplement. </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-size: 8pt; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 8pt; border-bottom: Black 1pt solid; text-align: center"><B>Per Share</B></TD><TD NOWRAP STYLE="font-size: 8pt; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-size: 8pt; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 8pt; border-bottom: Black 1pt solid; text-align: center"><B>Total</B></TD><TD NOWRAP STYLE="font-size: 8pt; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 8pt">Public offering price</TD><TD STYLE="width: 1%; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 8pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 8pt; text-align: right">1.00</TD><TD STYLE="width: 1%; font-size: 8pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 8pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 8pt; text-align: right">4,000,000.00</TD><TD STYLE="width: 1%; font-size: 8pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">Placement agent&rsquo;s fees<SUP>(1)</SUP></FONT></TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; text-align: left">$</TD><TD STYLE="font-size: 8pt; text-align: right">0.06</TD><TD STYLE="font-size: 8pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; text-align: left">$</TD><TD STYLE="font-size: 8pt; text-align: right">240,000.00</TD><TD STYLE="font-size: 8pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 8pt; text-align: left">Proceeds, before expenses, to us</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; text-align: left">$</TD><TD STYLE="font-size: 8pt; text-align: right">0.94</TD><TD STYLE="font-size: 8pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; text-align: left">$</TD><TD STYLE="font-size: 8pt; text-align: right">3,760,000.00</TD><TD STYLE="font-size: 8pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 0in 1pt 9pt"><DIV STYLE="font-size: 1pt; border-top: black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-left: 0.125in; text-indent: 0in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD>
    <TD STYLE="width: 97%; padding-left: 9pt"><FONT STYLE="font-size: 8pt">We have also agreed to pay the placement agent a
    management fee in the amount equal to 1.0% of the aggregate gross proceeds in this offering and reimburse the placement agent
    for certain offering-related expenses. See &ldquo;Plan of Distribution.&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to pay the placement agent
a placement agent fee in an amount equal to 6.0% of the aggregate gross proceeds in this offering. Because there is no minimum
offering amount required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and
proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set
forth above. See &ldquo;Plan of Distribution&rdquo; for more information on this offering and the placement agent arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement
or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivery of the shares of common stock is
expected to be made on or about January 12, 2018, subject to customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>H.C. Wainwright &amp; Co.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
January 10, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 89%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid"><B>Prospectus Supplement</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">About this Prospectus Supplement</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">S-ii</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Prospectus Supplement Summary</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">S-1</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">S-5</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">S-7</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">S-9</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_013">Selected Financial Data</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_013">S-10</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">S-12</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">S-13</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">S-13</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">S-13</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">S-13</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 89%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid"><B>Prospectus</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_001"><FONT STYLE="font-size: 10pt">SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_001"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_002"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_002"><FONT STYLE="font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_003"><FONT STYLE="font-size: 10pt">THE SECURITIES WE MAY OFFER</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_003"><FONT STYLE="font-size: 10pt">4</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_004"><FONT STYLE="font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_004"><FONT STYLE="font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_005"><FONT STYLE="font-size: 10pt">7</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_006"><FONT STYLE="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_006"><FONT STYLE="font-size: 10pt">8</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_007"><FONT STYLE="font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_007"><FONT STYLE="font-size: 10pt">12</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_008"><FONT STYLE="font-size: 10pt">LEGAL OWNERSHIP OF SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_008"><FONT STYLE="font-size: 10pt">14</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_009"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_009"><FONT STYLE="font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_010"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_010"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_011"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_011"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_012"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><A HREF="#b_012"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have not, and the placement agent
has not, authorized anyone to provide you with information that is different from that which is contained in or incorporated by
reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized
for use in connection with this offering. We are not, and the placement agent is not, making an offer to sell these securities
in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus
supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying
prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only
as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed
since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference
in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use
in connection with this offering, in their entirety before making an investment decision. You should also read and consider the
information in the documents to which we have referred you in the sections of this prospectus supplement entitled &ldquo;Where
You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference.&rdquo; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.5pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS SUPPLEMENT
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document is in two parts. The first part is the prospectus
supplement, which describes the specific terms of the common stock being offered by us, and also adds to and updates information
contained in the accompanying prospectus and the documents incorporated by reference. The second part, the accompanying prospectus,
including the documents incorporated by reference therein, provides more general information, some of which may not apply to this
offering of common stock. Generally, when we refer to this prospectus, we are referring to both parts of this document combined.
To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information
contained in the accompanying prospectus or in any document incorporated by reference that was filed with the Securities and Exchange
Commission, or SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information in this
prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a
later date &mdash; for example, a document incorporated by reference in the accompanying prospectus &mdash; the statement in the
document having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains references to
our trademarks and to trademarks and trade names belonging to other entities. Solely for convenience, trademarks and trade names
referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <SUP>&reg;</SUP> or
<SUP>TM</SUP> symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert,
to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&rsquo;
trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_002"></A><B>PROSPECTUS SUPPLEMENT SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights information
contained in other parts of this prospectus supplement or incorporated by reference into this prospectus supplement from our filings
with the SEC listed in the section of the prospectus supplement entitled &ldquo;Incorporation of Certain Information by Reference.&rdquo;
Because it is only a summary, it does not contain all of the information that you should consider before purchasing our shares
of common stock in this offering and it is qualified in its entirety by, and should be read in conjunction with, the more detailed
information appearing elsewhere or incorporated by reference into this prospectus supplement. You should read the entire prospectus
supplement, the registration statement of which this prospectus supplement is a part, and the information incorporated by reference
herein in their entirety, including the &ldquo;Risk Factors&rdquo; and our financial statements and the related notes incorporated
by reference into this prospectus supplement, before purchasing our shares of common stock in this offering. Unless the context
requires otherwise, references in this prospectus supplement to &ldquo;AmpliPhi,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and
&ldquo;our&rdquo; refer to AmpliPhi Biosciences Corporation together with its wholly owned subsidiaries.</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotechnology company pioneering
the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. Phages have powerful and
highly selective mechanisms of action that permit them to bind to and kill specific bacteria. We believe that phages represent
a promising means to treat bacterial infections, especially those that have developed resistance to current therapies, including
the so-called multi-drug-resistant or &ldquo;superbug&rdquo; strains of bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The extensive use of antibiotics since
the beginning of the modern antibiotics era in the 1940s has resulted in drug resistance among many disease-causing bacteria. According
to the U.S. Centers for Disease Control and Prevention, or CDC, resistance to antibiotics threatens to reverse many of the key
medical advances of the last half-century. Examples of clinically important microbes that are rapidly developing resistance to
available antimicrobials, many of which are included on the World Health Organization Priority Pathogens List published in February
2017, include bacteria that cause skin, bone, lung and bloodstream infections (e.g., <I>Staphylococcus aureus, </I>or <I>S. aureus</I>,
and methicillin-resistant <I>S. aureus</I>, or MRSA), pneumonia and lung infections in both community and hospital settings and
cystic fibrosis, or CF, patients (e.g., <I>S. aureus</I>, <FONT STYLE="background-color: white"><I>Acinetobacter baumannii, or</I></FONT><I>
A. baumanii, Pseudomonas aeruginosa</I>, or <I>P. aeruginosa,</I> and <FONT STYLE="background-color: white"><I>Klebsiella pneumonia,
or</I></FONT><I> K. pneumoniae</I>), meningitis (e.g., <FONT STYLE="background-color: white"><I>Streptococcus pneumonia, or</I></FONT><I>
S. pneumonia</I>), urinary tract and gastrointestinal infections (e.g., <I>P. aeruginosa, E. coli</I> and <FONT STYLE="background-color: white"><I>Clostridium
difficile, or</I></FONT><I> C. difficile</I>). As phages kill bacteria in ways entirely unlike the mechanisms used by traditional
antibiotics, we believe that most multi-drug resistant bacteria will be susceptible to phage therapy. Furthermore, should resistant
bacteria emerge or evolve, we believe it will remain possible to identify phages that can effectively kill these resistant bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to be the leading developer
of phage therapeutics. We are combining our expertise in the manufacture of drug-quality bacteriophages and our proprietary approach
and expertise in identifying, characterizing and developing naturally occurring bacteriophages with that of collaboration partners
in bacteriophage biology, synthetic biology and manufacturing, to develop state-of-the-art bacteriophage products. We are developing
phage products to combat multi- or pan-drug-resistant bacterial pathogens, leveraging advances in sequencing and molecular biology.
We have developed certain phage combinations that we believe maximize efficacy and minimize phage resistance. We currently have
product candidates in clinical and preclinical development for the treatment of <I>S. aureus</I> infections, including MRSA and
<I>P. aeruginosa</I> infections. We intend to develop these product candidates for the treatment of serious or life-threatening,
multi-drug resistant, or MDR, infections. We also intend to seek to advance our chronic rhinosinusitis, or CRS, program and preclinical
CF program through partnerships, arrangements and/or with additional outside funding. In April 2017, the U.S. Food and Drug Administration,
or FDA, provided positive feedback on our previously submitted detailed development proposal to commence a Phase 2 trial with our
proprietary bacteriophage cocktail AB-SA01 for the treatment of antibiotic-resistant <I>S. aureus</I> infections in patients with
CRS, which feedback followed a Type B telephonic meeting held with us on February 21, 2017. In the official minutes from the meeting,
the FDA acknowledged that phage therapy is an exciting approach to treatment of multi-drug-resistant organisms and expressed a
commitment to addressing the unique regulatory challenges that might arise during product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe our bacteriophage technology may have unique
application in the area of targeted medicine, and in May 2017, we announced a new strategic emphasis on targeted therapies for
serious or life-threatening antibiotic-resistant infections. In particular, we believe our bacteriophage technology can be used
to develop targeted therapies for patients who suffer from serious or life-threatening antibiotic-resistant bacterial infections
and who have limited or no other satisfactory treatment options. Moreover, we believe our ability to target phage therapies for
antibiotic-resistant infections, combined with the ability of bacteriophage to re-sensitize drug-resistant populations to antibiotics,
represents what could be a powerful tool against the growing challenge of antibiotic-resistant infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under existing single-patient expanded
access guidelines (also referred to as &ldquo;compassionate use&rdquo;), established by the regulatory agencies, we have begun
to provide targeted phage therapies to patients suffering from severe MDR infections who have failed prior therapies. We believe
this strategic approach will not only provide potential benefit to patients to whom we are able to provide targeted phage therapies,
but also provide the clinical and microbiological data from these cases that we expect to support the potential validation of the
clinical utility of phage therapy, identify the most promising indications for further clinical development of our AB-SA01 and
AB-PA01 product candidates for <I>S. aureus</I> and <I>P. aeruginosa</I>, define optimal treatment regimens, and inform our future
discussions with the FDA and other regulatory agencies in 2018 or later on defining a potential path to market approval. We are
initially making targeted phage therapies available under the appropriate expanded access guidelines in the United States and in
Australia, where we collaborate with select leading hospitals and key opinion leaders to identify and select eligible patients.
We believe that the United States and Australia have a favorable regulatory framework and clinical expertise with respect to treating
patients under single-patient expanded access guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our emphasis on targeted therapies builds
upon our prior successes using tailored bacteriophage therapies under emergency investigational new drug applications to treat
individual patients battling life-threatening, MDR bacterial pathogens who had exhausted their treatment options. In March 2016,
we collaborated with several academic institutions and a U.S. Navy laboratory to produce a targeted bacteriophage therapy that
successfully treated a critically ill, comatose patient with an MDR <I>A. baumannii</I> infection. Shortly after phage therapy
was initiated, the patient emerged from the coma and continued to improve under an ongoing combination of phage and antibiotic
therapies until the infection was cleared. To date, the infection has not returned. Additionally, in December 2007 our wholly owned
subsidiary, Special Phage Services, was instrumental in developing a targeted phage therapy that, together with a course of antibiotics,
eliminated a previously antibiotic-resistant P. aeruginosa infection in the bladder of a female cancer patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are implementing the targeted therapy
strategy and, through the date of this prospectus supplement have provided bacteriophage investigational therapies AB-SA01 and
AB-PA01 for seven patients suffering from serious and life-threatening infections under emergency investigational new drug applications,
or INDs, in the United States or Special Access Scheme Category&nbsp;A in Australia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 3, 2018, we announced interim,
topline results for the first seven patients treated with our investigational bacteriophage product candidates, AB-SA01 and AB-PA01,
under our ongoing single-patient expanded access program. The patients in this program were severely ill and unresponsive to antibiotic
treatment at the time of enrollment and were treated under emergency investigational new drug applications in the United States
or under the Special Access Scheme in Australia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Of the seven patients treated, four patients
received AB-SA01, administered intravenously, for treatment of&nbsp;<I>Staphylococcus aureus</I>&nbsp;infection, and three patients
received AB-PA01, administered intravenously or in some cases by nebulizer, for treatment of&nbsp;<I>Pseudomonas aeruginosa</I>&nbsp;infection.
The bacteriophage therapy was administered along with the treating physician&rsquo;s choice of best available antibiotic therapy.
Treated patients suffered from bacteremia, endocarditis and lung infections, and both AB-SA01 and AB-PA01 were well tolerated in
all patients with no treatment-related serious adverse events reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Treatment success, defined as complete
resolution or significant improvement of baseline signs and symptoms, was reported in six of the seven patients (86%) by physician&rsquo;s
assessment. One patient was determined to be a treatment failure due to death, which occurred during surgery after three days
of bacteriophage treatment. The treating physician determined that the death was unrelated to treatment with bacteriophage therapy.
The 28-day all-cause mortality rate was 14%. No additional deaths occurred within 90 days following initiation of therapy, and
patient follow-up is continuing. Based on the APACHE II scores (a validated critical care scoring system predictive of mortality)
of the seven patients prior to initiation of bacteriophage therapy, the predicted mortality rate for this patient group was 46%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No bacterial isolates resistant to the bacteriophage
therapeutics were detected during the bacteriophage treatment course. Additional analyses of these data are ongoing, and presentations
or publications of the detailed results are planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Preliminary Financial Results </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2017, we had approximately
$5.1&nbsp;million of cash and cash equivalents. This amount is unaudited and preliminary, is subject to completion of financial
closing procedures that could result in changes to the amount, and does not present all information necessary for an understanding
of our financial condition as of December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate and Other Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated under the laws of
the State of Washington in March 1989 as a wholly owned subsidiary of Immunex Corporation and began operations as an independent
company in 1992 as Targeted Genetics Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2011, we completed the acquisition
of Biocontrol Ltd, an antimicrobial biotechnology company based in the United Kingdom, with the goal of developing their phage
therapy programs using funding from the sale of our legacy gene therapy assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2011, we changed our name to
&ldquo;AmpliPhi Biosciences Corporation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2012, we completed the acquisition
of Special Phage Holdings Pty Ltd, a company based in Australia, which we refer to as SPH, with the goal of combining SPH&rsquo;s
research on addressing the rapidly escalating problem of antibiotic resistance through the development of a series of bacteriophage-based
treatments into our own development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2015, we effected a 1-for-50
reverse split of our common stock. The share and per share information described in this prospectus that occurred prior to the
reverse split have been adjusted to give retrospective effect to the reverse split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2017, we effected a 1-for-10 reverse
split of our common stock. The share and per share information described in this prospectus supplement that occurred prior to the
reverse split have been adjusted to give retrospective effect to the reverse split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at 3579 Valley Centre Drive, Suite 100, San Diego, California 92130. The telephone number at our principal executive office is
(858) 829-0829. Our website address is <I>www.ampliphibio.com</I>. Our website and the information contained on, or that can be
accessed through, our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus
supplement. You should not rely on our website or any such information in making your decision whether to purchase our shares
of common stock in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt">Common stock offered by us in this offering </FONT></TD>
    <TD STYLE="width: 67%"><FONT STYLE="font-size: 10pt">4,000,000 shares of our common stock. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt">Offering price </FONT></TD>
    <TD STYLE="width: 67%"><FONT STYLE="font-size: 10pt">$1.00 per share of common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common stock outstanding</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">immediately after this offering</P></TD>
    <TD STYLE="width: 67%; text-align: justify"><FONT STYLE="font-size: 10pt">13,325,595 shares (assuming the sale of all shares
    covered by this prospectus supplement). </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-bottom: 1pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Use of proceeds </FONT></TD>
    <TD STYLE="width: 67%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We estimate that our net proceeds
    from this offering will be approximately $3.5 million after deducting estimated placement agent fees and other
    estimated offering expenses payable by us (assuming the sale of all shares covered by this prospectus supplement). We plan to
    use the net proceeds of this offering for general corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-bottom: 1pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Risk factors </FONT></TD>
    <TD STYLE="width: 67%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Investing in our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-5 of this prospectus supplement. </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt">Exchange listing </FONT></TD>
    <TD STYLE="width: 67%; text-align: justify"><FONT STYLE="font-size: 10pt">Our common stock is listed on The NYSE American under the symbol &ldquo;APHB.&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock to
be outstanding immediately after this offering is based on 9,325,595 shares of our common stock outstanding as of September 30,
2017. Unless otherwise indicated, the number of shares of common stock presented in this prospectus supplement excludes as of September
30, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -33.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">1,116,765 shares of common stock issuable upon the exercise of outstanding stock options, at a weighted-average exercise price
of&thinsp; $3.19 per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -33.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">4,580 shares of common stock reserved for future grant under our 2016 Equity Incentive Plan, or the 2016 plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -33.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">21,016 shares of common stock reserved for future issuance under our 2016 Employee Stock Purchase Plan, or the ESPP; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -33.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">8,712,220 shares of common stock issuable upon the exercise of outstanding warrants, at a weighted-average exercise price of&thinsp;
$2.91 per share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_003"></A><B>RISK FACTORS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our common stock involves
a high degree of risk. Our business, prospects, financial condition or operating results could be materially adversely affected
by the risks identified below, as well as other risks not currently known to us or that we currently consider immaterial. The trading
price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing
the risks described below, you should also refer to the information contained in our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2017 and other documents which are incorporated by reference in this prospectus supplement and the accompanying
prospectus in their entirety, and other documents that we file from time to time with the SEC. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to This Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Management will have broad discretion
as to the use of the proceeds from this offering, and we may not use the proceeds effectively. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion
in the application of the net proceeds from this offering, including for any of the purposes described in the section entitled
&ldquo;Use of Proceeds,&rdquo; and you will not have the opportunity as part of your investment decision to assess whether the
net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the
net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management may
not apply the net proceeds from this offering in ways that ultimately increase the value of your investment. The failure by our
management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this
offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our
stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail
to achieve expected financial results, which could cause our stock price to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate and
substantial dilution in the net tangible book value per share of the common stock you purchase. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the price per share of our
common stock being offered is substantially higher than the net tangible book value per share of our common stock, you will
suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering.
As of September 30, 2017, our net tangible book value was approximately $4.8 million, or $0.52 per share. Based on the public
offering price of $1.00 per share and our net tangible book value as of September 30, 2017, if you purchase shares of common
stock in this offering, you will suffer immediate and substantial dilution of $0.38 per
share with respect to the net tangible book value of the common stock you purchase in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to raise additional
capital in the future to continue operations, which may not be available on acceptable terms, or at all. Failure to obtain this
necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have had recurring losses from operations,
negative operating cash flow and an accumulated deficit. We do not generate any cash from operations and must raise additional
funds in order to continue operating our business. Even if this offering is successful, we expect to continue to fund our operations
primarily through equity and debt financings in the future. If additional capital is not available to us when needed or on acceptable
terms, we may not be able to continue to operate our business pursuant to our business plan or we may have to discontinue our operations
entirely. As of December 31, 2017, we had cash and cash equivalents of $5.1 million. We estimate that we will receive net proceeds
of approximately $3.5 million from the sale of the securities offered by us in this offering,
if all of the shares being offered by this prospectus supplement are sold. However, there is no minimum offering amount required
as a condition to closing this offering, and therefore the actual total offering proceeds to us, before expenses, may be substantially
less. In addition, we cannot provide assurances that our plans will not change or that changed circumstances will not result in
the depletion of our capital resources more rapidly than we currently anticipate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Developing drugs and conducting clinical
trials is expensive. Our future funding requirements will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the costs and timing of our research and development activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the progress and cost of our clinical trials and other research and development activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the cost and timing of securing manufacturing capabilities for our clinical product candidates
and commercial products, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the terms and timing of any collaborative, licensing, acquisition or other arrangements that we
may establish;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">whether and when we receive future Australian tax rebates, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the costs and timing of seeking regulatory approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the costs of filing, prosecuting, defending and enforcing any patent applications, claims, patents
and other intellectual property rights; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the costs of lawsuits involving us or our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may seek funds through arrangements
with collaborators or others that may require us to relinquish rights to the products candidates that we might otherwise seek to
develop or commercialize independently. We cannot be certain that we will be able to enter into any such arrangements on reasonable
terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may seek to raise capital through a
variety of sources, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the public equity market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">private equity financings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborative arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">licensing arrangements; and/or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">public or private debt.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8203;Any additional fundraising efforts
may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our product candidates. Our ability to raise additional funds will depend, in part, the success of our preclinical studies and
clinical trials and other product development activities, regulatory events, our ability to identify and enter into in-licensing
or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related
to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds
will be available to us when required or on acceptable terms, if at all. Raising additional capital through the sale of securities
could cause significant dilution to our stockholders. If we are unable to secure additional funds on a timely basis or on acceptable
terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some
or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition of our company
by a third party at a price that may result in a loss on investment for our stockholders, enter into arrangements that may require
us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease
operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results
of operations. Moreover, if we are unable to obtain additional funds on a timely basis, there will be substantial doubt about
our ability to continue as a going concern and increased risk of insolvency and loss of investment by our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There may be future sales of our
securities or other dilution of our equity, which may adversely affect the market price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms and conditions
of the securities purchase agreements we have entered into with certain institutional investors in this offering which will
restrict our ability to sell common stock or common stock equivalents for a period of 60 days, we are generally not
restricted from issuing additional common stock, including any securities that are convertible into or exchangeable for, or
that represent the right to receive, common stock. The market price of our common stock could decline as a result of sales of
common stock or securities that are convertible into or exchangeable for, or that represent the right to receive, common
stock after this offering or the perception that such sales could occur.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_004"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
prospectus, including the documents that we incorporate by reference herein and therein, contain statements that are not strictly
historical in nature and are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as
amended, or the Securities Act, and within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended,
or the Exchange Act. These forward-looking statements are subject to the &ldquo;safe harbor&rdquo; created by Section&nbsp;27A
of the Securities Act and Section&nbsp;21E of the Exchange Act and may include, but are not limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
prospectus, including the documents that we incorporate by reference herein and therein, contain forward-looking statements. The
forward-looking statements are contained principally in the sections entitled &ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and &ldquo;Business&rdquo;
in this prospectus supplement, the accompanying prospectus or the documents incorporated herein by reference. These statements
relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors
which may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited
to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our estimates regarding anticipated operating losses, capital
requirements and needs for additional funds;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our ability to raise additional capital when needed and
to continue as a going concern;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our ability to manufacture, or otherwise secure the manufacture
of, sufficient amounts of our product candidates for our preclinical studies and clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our clinical development and other research and development
plans and expectations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our ability to select combinations of phages to formulate
our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the safety and efficacy of our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the anticipated regulatory pathways for our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our ability to successfully complete preclinical and clinical
development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected
timeframes or at all;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the content and timing of submissions to and decisions
made by the U.S. Food and Drug Administration and other regulatory agencies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our ability to leverage the experience of our management
team;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our ability to attract and keep management and other key
personnel;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the capacities and performance of our suppliers, manufacturers,
contract research organizations and other third parties over whom we have limited control;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the actions of our competitors and success of competing
drugs that are or may become available;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our expectations with respect to future growth and investments
in our infrastructure, and our ability to effectively manage any such growth;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our expectations with respect to our new targeted phage
therapies strategy, including the ability to demonstrate on the timeframe we anticipate, or at all, proof-of-concept sufficient
to support regulatory approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the size and potential growth of the markets for any of
our product candidates, and our ability to capture share in or impact the size of those markets;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the benefits of our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">market and industry trends;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the outcome of any litigation in which we or any of our
officers or directors may be involved;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the effects of government regulation and regulatory developments,
and our ability and the ability of the third parties with whom we engage to comply with applicable regulatory requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the accuracy of our estimates regarding future expenses,
revenues, capital requirements and need for additional financing;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our expectations regarding future planned expenditures;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our ability to achieve and maintain effective internal
control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our expectations regarding the period during which we qualify
as an emerging growth company under the JOBS Act;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our ability to obtain, maintain and successfully enforce
adequate patent and other intellectual property protection of any of our products and product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our expected use of the net proceeds from this offering;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
ability to operate our business without infringing the intellectual property rights of others.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In some cases, you can identify these statements
by terms such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
&ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative of those terms, and similar expressions that convey
uncertainty of future events or outcomes. These forward-looking statements reflect our management&rsquo;s beliefs and views with
respect to future events and are based on estimates and assumptions as of the date of this prospectus and are subject to risks
and uncertainties. We discuss many of these risks in greater detail in the documents incorporated by reference herein, usually
under the heading &ldquo;Risk Factors.&rdquo; Moreover, we operate in a very competitive and rapidly changing environment. New
risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all
factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially
from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance
on these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should carefully read this prospectus
supplement, the accompanying prospectus and the documents that we incorporate by reference completely and with the understanding
that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements
in this prospectus supplement and the accompanying prospectus by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as required by law, we assume no obligation to update
these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated
in any forward-looking statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_005"></A><B>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the net proceeds from
the sale of shares of our common stock offered under this prospectus supplement, after deducting estimated placement agent fees
and estimated offering expenses payable by us, will be $3.5 million if we sell the
maximum amount of common stock offered hereby. However, this is a best efforts offering with no minimum, and we may not sell all
or any of these shares; as a result, we may receive significantly less in net proceeds, and the net proceeds received may not be
sufficient to continue to operate our business.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds from
this offering for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development
expenses and general and administrative expenses. We may also use a portion of the net proceeds from this offering to in-license,
invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans,
commitments or agreements with respect to any acquisitions. As of the date of this prospectus supplement, we cannot specify with
certainty all of the particular uses of the proceeds from this offering. Accordingly, we will retain broad discretion over the
use of such proceeds. Pending the use of the net proceeds from this offering, we intend to invest the net proceeds in investment-grade,
interest-bearing instruments.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors are cautioned that the proceeds
from this offering are expected to be sufficient to enable us to continue operations for only a short period of time. We expect
that we will have to raise additional capital through the sale of additional equity or convertible debt securities. It may be difficult
for us to raise additional funds when needed and on favorable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.8pt 0pt 70pt; text-align: center"><B><A NAME="a_013"></A>SELECTED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following selected financial
data should be read together with our financial statements and related notes appearing in our Annual Report on Form 10-K for the
year ended December&nbsp;31, 2016, filed with the SEC on March&nbsp;27, 2017. The selected financial data in this section are not
intended to replace our financial statements and the related notes. Our historical results are not necessarily indicative of the
results that may be expected in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following selected financial
data have been adjusted to give retrospective effect to the 1-for-10 reverse stock split which was effected in April&nbsp;2017.
Ernst &amp; Young LLP has not audited, reviewed, compiled, or performed any procedures with respect to the per share data effected
by the 1-for-10 reverse stock split. Accordingly, Ernst &amp; Young LLP does not express an opinion or any other form of assurance
with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we are a smaller reporting
company and are not required to include selected financial data disclosure, we are including the following selected financial data
for the periods indicated for purposes of showing the retrospective effect of the 1-for-10 reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.8pt 0pt 70pt; text-align: center"><B>AmpliPhi Biosciences Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.8pt 0pt 70pt; text-align: center"><B>Consolidated Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.8pt 0pt 70pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year
    Ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif">Revenue</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">260,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">475,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,678,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,992,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,413,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,710,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Impairment charges</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">9,547,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">23,638,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">10,702,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(23,378,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(10,227,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivative liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,538,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,940,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(554,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(302,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total other income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">3,984,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">9,638,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss before income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(19,394,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(589,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Income tax benefit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">556,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">73,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(18,838,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(516,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Excess of fair value of consideration transferred on
    conversion of Series B redeemable convertible preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,580,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accretion of Series B redeemable
    convertible preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(1,858,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(10,278,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">(24,276,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">(10,794,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Per share information:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Loss per share of common
    stock&thinsp;&ndash;&thinsp;basic &amp; diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">(24.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">(19.95</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Weighted average number of shares of common
    stock     outstanding&thinsp;&ndash;&thinsp; basic &amp; diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">983,846</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">541,120</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.8pt 0pt 70pt; text-align: center"><B>AmpliPhi Biosciences Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.8pt 0pt 70pt; text-align: center"><B>Consolidated Balance Sheet Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.8pt 0pt 70pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Consolidated Balance Sheet Data</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,711,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">9,370,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Working capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,775,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,631,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,195,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31,493,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,472,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,889,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(381,360,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(362,522,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,723,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,714,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.8pt 0pt 70pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_006"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to an engagement agreement, we
have engaged H.C. Wainwright &amp; Co., LLC as our exclusive placement agent, to solicit offers to purchase the common stock offered
by this prospectus supplement. The placement agent is not purchasing any common stock for its own account in this offering, and
is not required to arrange the purchase or sale of any additional specific number or dollar amount of the securities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent has agreed to use its
reasonable best efforts to arrange for the sale of all of the securities in this offering. There is no requirement that any minimum
number of shares of common stock or dollar amount of common stock be sold in this offering and there can be no assurance that we
will sell all or any of the common stock being offered. Certain large investors executed a securities purchase
agreement with us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently anticipate that the closing
of this offering will occur on or about January 12, 2018, subject to customary closing
conditions. On the closing date, the following will occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">we will receive funds in the amount of the aggregate purchase price; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the placement agent will receive the placement agent fees in accordance with the terms of the engagement agreement; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">we will deliver the shares of common stock to the investors. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to pay the placement agent
a placement agent fee an amount equal to 6.0 % of the aggregate gross proceeds in this offering and management fee of 1.0% of the
gross proceeds of this offering. We have also agreed to reimburse H.C. Wainwright &amp; Co., LLC for its expenses in connection
with this offering on a non-accountable basis in an amount equal to $25,000 and reimbursement for the placement agent's legal
fees and expenses in the amount of up to $100,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the per share
and total fees we will pay in connection with the sale of the common stock, assuming the purchase of all of the common stock we
are offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Per share placement agent fees </TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.06</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">240,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate the total expenses of this
offering which will be payable by us, excluding the placement agent fees, will be approximately $250,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify the placement
agent and certain other persons against certain liabilities relating to or arising out of the placement agent&rsquo;s activities
under the engagement agreement. We have also agreed to contribute to payments that the placement agent may be required to make
in respect of such liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">H.C. Wainwright &amp; Co., LLC may be deemed
to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, and any commissions received
by it and any profit realized on the resale of the common stock sold by it while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act of 1933, as amended. As an underwriter, H.C. Wainwright &amp; Co., LLC would
be required to comply with the requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934,
as amended, including, without limitation, Rule 415(a)(4) under the Securities Act of 1933, as amended, and Rule 10b-5 and Regulation
M under the Securities Exchange Act of 1934, as amended. These rules and regulations may limit the timing of purchases and sales
of shares of common stock by H.C. Wainwright &amp; Co., LLC acting as principal. Under these rules and regulations, H.C. Wainwright
&amp; Co., LLC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">may not engage in any stabilization activity in connection with our securities; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Securities Exchange Act of 1934, as amended, until it has completed its participation in the distribution. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_007"></A>LEGAL MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the securities offered
by this prospectus supplement and the accompanying prospectus will be passed upon for us by Cooley LLP, San Diego, California.
The placement agent is being represented by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_008"></A><B>EXPERTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ernst &amp; Young LLP, independent registered
public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year
ended December&nbsp;31, 2016, as set forth in their report (which contains an explanatory paragraph describing conditions that
raise substantial doubt about our ability to continue as a going concern as described in Note 2 to the consolidated financial statements),
which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are
incorporated by reference in reliance on Ernst &amp; Young LLP&rsquo;s report, given on their authority as experts in accounting
and auditing.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_009"></A><B>WHERE YOU CAN FIND MORE INFORMATION
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
prospectus are part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and do not contain
all the information set forth in the registration statement. Whenever a reference is made in this prospectus supplement or the
accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should
refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated
by reference in this prospectus supplement and the accompanying prospectus for a copy of such contract, agreement or other document.
Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current
reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the internet at
the SEC&rsquo;s website at http://www.sec.gov. You may also read and copy any document we file at the SEC&rsquo;s Public Reference
Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation
of the Public Reference Room.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_010"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate
by reference&rdquo; information from other documents that we file with it, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus.
Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border: white 1pt solid">We incorporate
by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents
listed below (other than current reports or portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed
on such form that are related to such items and other portions of documents that are furnished, but not filed, pursuant to applicable
rules promulgated by the SEC) that we have filed with the SEC (Commission File No. 001-37544):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our annual report on Form 10-K for the year ended December
31, 2016, filed with the SEC on March 27, 2017;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our quarterly reports on Form 10-Q for the quarters ended
March 31, 2017, June 30, 2017 and September&nbsp;30, 2017, filed with the SEC on May 15, 2017, August 14, 2017 and November 14,
2017, respectively;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our current reports on Form 8-K and any amendments thereto
on Form 8-K/A, filed with the SEC on February&nbsp;2, 2017, April 4, 2017, April 19, 2017, April&nbsp;24, 2017, May 1, 2017, May
8, 2017, May 10, 2017, June 5, 2017, June 30, 2017, September 11, 2017, September 20, 2017, December 14, 2017 and January 3, 2018;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the information specifically incorporated by reference
into our annual report on Form 10-K for the year ended December 31, 2016 from our Definitive Proxy Statement on Schedule 14A,
filed with the SEC on July 24, 2017; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the description of our common stock contained in our registration
statement on Form 8-A, filed with the SEC on August 18, 2015, including all amendments and reports filed for the purpose of updating
such description.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, all documents subsequently
filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offering (excluding
any information furnished rather than filed) shall be deemed to be incorporated by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide to each person, including
any beneficial owners, to whom a prospectus is delivered, a copy of any or all of the reports or documents that have been incorporated
by reference in the prospectus contained in the registration statement but not delivered with the prospectus. We will provide these
reports or documents upon written or oral request at no cost to the requester. You should direct any written requests for documents
to AmpliPhi Biosciences Corporation, Attn: Chief Financial Officer, 3579 Valley Centre Drive, Suite 100, San Diego, California
92130. You may also telephone us at (858) 829-0829.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Rule 412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent
that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>$75,000,000
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="tv483099_img2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Common
Stock Warrants</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">From
time to time, we may sell up to an aggregate of $75,000,000 of our common stock or warrants to purchase common stock, individually
or in units, in amounts, at prices and on terms described in one or more supplements to this prospectus. We may also authorize
one or more free writing prospectuses to be provided to you in connection with these offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our common stock is traded on the NYSE MKT
under the trading symbol &ldquo;APHB.&rdquo; On April 27, 2016, the last reported sale price of our common stock on the NYSE MKT
was $3.20. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on the
NYSE MKT or other securities exchanges of the securities covered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our principal executive offices are located
at 3579 Valley Centre Drive, San Diego, California 92130, and our telephone number at that address is (858) 829-0829.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">You should
read this prospectus and any prospectus supplement carefully before you invest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B>INVESTING IN OUR SECURITIES INVOLVES A
HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES REFERENCED UNDER THE HEADING &ldquo;RISK FACTORS&rdquo;
ON PAGE 4 OF THIS PROSPECTUS AS WELL AS THOSE CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS,
AND UNDER SIMILAR HEADINGS IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B>This prospectus may not be used to offer
or sell any securities unless accompanied by a prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">As of the date of this prospectus, the aggregate
market value of our outstanding common stock held by non-affiliates, or public float, was approximately $29.5 million, based on
6,066,466 shares of outstanding common stock held by non-affiliates as of the date of this prospectus, at a price of $4.86 per
share, which was the last reported sale price of our common stock on the NYSE MKT on March 22, 2016. Pursuant to General Instruction
I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement of which this prospectus is a part
in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our
public float remains below $75.0 million. As of the date hereof, we have not offered any securities pursuant to General Instruction
I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The securities may be sold directly by us
to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed
basis. For additional information on the methods of sale, you should refer to the section entitled &ldquo;Plan of Distribution&rdquo;
in this prospectus and in the applicable prospectus supplement. If any agents or underwriters are involved in the sale of any securities
with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions,
discounts and options to purchase additional securities will be set forth in a prospectus supplement. The price to the public of
such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this Prospectus is May 13,
2016.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 88%">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_001"><FONT STYLE="font-size: 10pt">SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_001"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_002"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_002"><FONT STYLE="font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_003"><FONT STYLE="font-size: 10pt">THE SECURITIES WE MAY OFFER</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_003"><FONT STYLE="font-size: 10pt">4</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_004"><FONT STYLE="font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_004"><FONT STYLE="font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_005"><FONT STYLE="font-size: 10pt">7</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_006"><FONT STYLE="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_006"><FONT STYLE="font-size: 10pt">8</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_007"><FONT STYLE="font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_007"><FONT STYLE="font-size: 10pt">12</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_008"><FONT STYLE="font-size: 10pt">LEGAL OWNERSHIP OF SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_008"><FONT STYLE="font-size: 10pt">14</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_009"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_009"><FONT STYLE="font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_010"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_010"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_011"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_011"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><A HREF="#b_012"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><A HREF="#b_012"><FONT STYLE="font-size: 10pt">19</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We have not authorized anyone to provide
you with information different from the information contained in or incorporated by reference in this prospectus, any applicable
prospectus supplement and any related free writing prospectus that we may authorize to be provided to you. No dealer, salesperson
or other person is authorized to give any information or to represent anything not contained or incorporated by reference in this
prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to
you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions
where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or
any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have
incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of
delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of our securities.
Our business, financial condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">This prospectus is part of a registration
statement on Form S-3 that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &ldquo;shelf&rdquo; registration
process. Under this shelf registration process, we may offer and sell, either individually or in combination, in one or more offerings,
any combination of the securities described in this prospectus, for total gross proceeds of up to $75,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">This prospectus provides you with a general
description of the securities we may offer. Each time we offer securities under this prospectus, we will provide a prospectus supplement
that will contain more specific information about the terms of those securities and the offering. We may also authorize one or
more free writing prospectuses to be provided to you that may contain material information relating to these offerings. We may
also add, update or change in the prospectus supplement (and in any related free writing prospectus that we may authorize to be
provided to you) any of the information contained in this prospectus or in the documents that we have incorporated by reference
into this prospectus. We urge you to carefully read this prospectus, any applicable prospectus supplement and any related free
writing prospectus, together with the information incorporated herein by reference as described under the headings &ldquo;Where
You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo; before buying any of the
securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_001"></A>SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>The following summary highlights information
contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the information that may be
important to purchasers of our securities. You should carefully read this prospectus, all documents incorporated by reference,
any prospectus supplement and any related free writing prospectus, and the additional information described under the caption &ldquo;Where
You Can Find More Information&rdquo; in this prospectus, before buying any of the securities being offered. References in this
prospectus to &ldquo;AmpliPhi,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer
to AmpliPhi Biosciences Corporation and its subsidiaries, on a consolidated basis, unless the context requires otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AmpliPhi Biosciences Corporation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We are a biotechnology company focused on
the discovery, development and commercialization of novel phage therapeutics. Phage therapeutics use bacteriophages, a family of
viruses, to kill pathogenic bacteria. Phages have powerful and highly selective mechanisms of action that permit them to target
and kill specific bacteria. We believe that phages represent a promising means to treat bacterial infections, especially those
that have developed resistance to current therapies, including the so-called multi-drug-resistant or &ldquo;superbug&rdquo; strains
of bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our goal is to be the leading developer of
phage therapeutics. We are combining our expertise in the manufacture of drug-quality bacteriophages and our proprietary approach
and expertise in identifying, characterizing and developing naturally occurring bacteriophages with that of our collaboration partners
in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The extensive use of antibiotics since their
discovery in the 1940s has resulted in drug resistance among many disease-causing bacteria. According to the U.S. Centers for Disease
Control and Prevention, resistance to antibiotics threatens to reverse many of the key medical advances of the last half-century.
Examples of clinically important microbes that are rapidly developing resistance to available antimicrobials include bacteria that
cause skin, bone, lung and bloodstream infections (e.g., <I>S. aureus</I> and methicillin-resistant <I>S. aureus</I>, or MRSA),
pneumonia and lung infections in both community and hospital settings and cystic fibrosis patients (e.g., <I>A. baumanii, P. aeruginosa,</I>
and <I>K. pneumoniae</I>), meningitis (e.g., <I>S. pneumonia</I>), urinary tract and gastrointestinal infections (e.g., <I>E. coli</I>
and <I>C. difficile</I>). As phages kill bacteria in ways entirely unlike the mechanisms used by traditional antibiotics, we believe
that multi-drug resistant bacteria will be susceptible to phage therapy. Furthermore, should resistant bacteria emerge, we believe
it will remain possible to identify phages that can effectively kill these resistant bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our lead product candidate is AB-SA01, for
the treatment of <I>S. aureus</I> infections, including MRSA. We also have another product candidate in earlier stage development,
AB-PA01 for the treatment of <I>P. aeruginosa</I> infections, and an additional discovery program, AB-CD01 for the treatment of
<I>C. difficile</I> infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We are developing our phage product candidates
using a proprietary discovery and development platform, which is designed for rapid identification, characterization and manufacturing
of multiple phage therapeutics. Each product candidate combines several carefully chosen phages, which target a specific disease-causing
bacterial pathogen such as <I>S. aureus, P. aeruginosa</I>, and <I>C. difficile</I>. We believe that the combination of our platform,
our manufacturing capability, our understanding of the regulatory and development requirements of bacteriophage therapeutics, and
the clinical and scientific expertise of our collaboration partners may enable the rapid advancement of phage therapeutics through
the clinic and the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate and Other Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We were incorporated under the laws of the
State of Washington in March 1989 as a wholly-owned subsidiary of Immunex Corporation and began operations as an independent company
in 1992 as Targeted Genetics Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">In January 2011, we completed the acquisition
of Biocontrol Ltd, an antimicrobial biotechnology company based in the United Kingdom, with the goal of developing their phage
therapy programs using funding from the sale of our legacy gene therapy assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">On February 22, 2011, we changed our name
to &ldquo;AmpliPhi Biosciences Corporation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">In November 2012, we completed the acquisition
of Special Phage Holdings Pty Ltd, a company based in Australia, which we refer to as SPH, with the goal of combining SPH&rsquo;s
research on addressing the rapidly escalating problem of antibiotic resistance through the development of a series of bacteriophage-based
treatments into our own development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our shares have been listed on the NYSE MKT
since August of 2015 and before that were traded on the OTCQB. The trading symbol for our common stock is &ldquo;APHB&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">In November 2015, our board of directors
approved a plan for us to reincorporate as AmpliPhi Biosciences Corporation in the State of Delaware, subject to the approval of
our shareholders. We may decide to abandon our plan to reincorporate in the State of Delaware at our election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our principal executive offices are located
at 3579 Valley Centre Drive, San Diego, California 92130. The telephone number at our principal executive offices is (858) 829-0829.
Our website address is <I>http://www.ampliphibio.com</I>. Our website and the information contained on, or that can be accessed
through, our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus. You
should not rely on our website or any such information in making your decision whether to purchase any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">This prospectus contains references to our
trademarks and to trademarks and trade names belonging to other entities. Solely for convenience, trademarks and trade names referred
to in this prospectus, including logos, artwork and other visual displays, may appear without the &reg; or <SUP>TM</SUP> symbols,
but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent
under applicable law, their rights thereto. We do not intend our use or display of other companies&rsquo; trade names or trademarks
to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being an Emerging Growth Company and a Smaller
Reporting Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We qualify as an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012. An &ldquo;emerging growth company&rdquo;
may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include,
but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">being permitted to present only two years of audited financial statements and only two years of related Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations in the documents incorporated by reference into this prospectus;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We may use these provisions until the last
day of our fiscal year following the fifth anniversary of the first sale of our equity securities pursuant to an effective registration
statement under the Securities Act of 1933, as amended, or the Securities Act, after we became a reporting company under the Securities
Exchange Act of 1934, as amended, or the Exchange Act, pursuant to our registration statement on Form 10 (File No. 000-23930).
However, if certain events occur prior to the end of such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo;
our annual gross revenues exceed $1.0 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period,
we will cease to be an emerging growth company prior to the end of such five-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We are also a &ldquo;smaller reporting company&rdquo;
as defined in Exchange Act and have elected to take advantage of certain of the scaled disclosures available to smaller reporting
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We have elected to take advantage of certain
of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage
of other reduced reporting requirements in future filings. As a result, the information that we provide to our shareholders may
be different than you might receive from other public reporting companies in which you hold equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The JOBS Act provides that an emerging growth
company can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably
elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards
as other public companies that are not emerging growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_002"></A>RISK FACTORS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">An investment in our securities involves
a high degree of risk. Prior to making a decision about investing in our securities, you should carefully consider the specific
risk factors discussed in the sections entitled &ldquo;Risk Factors&rdquo; contained in any applicable prospectus supplement and
our filings with the SEC, which are incorporated by reference in this prospectus, together with all of the other information contained
in this prospectus, any applicable prospectus supplement or free writing prospectus, or incorporated by reference in this prospectus.
These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently
known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described
in our SEC filings or any prospectus supplement or free writing prospectus that we may authorize to be provided to you, or any
additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially
and adversely affected. In that case, the trading price of our securities could decline and you might lose all or part of your
investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_003"></A><B>THE SECURITIES WE MAY OFFER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We may offer up to $75,000,000 of shares
of our common stock and/or warrants to purchase common stock from time to time under this prospectus at prices and on terms to
be determined by market conditions at the time of offering. This prospectus provides you with a general description of the securities
we may offer. Each time we offer a type or series of securities, we will provide a prospectus supplement that will describe the
specific amounts, prices and other important terms of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">A prospectus supplement and any related free
writing prospectus that we may authorize to be provided to you also may add, update or change information contained in this prospectus
or in documents we have incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This prospectus may not be used to offer or sell securities
unless it is accompanied by a prospectus supplement. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We may sell the securities directly to or
through agents, underwriters or dealers. We, and our agents, dealers or underwriters, reserve the right to accept or reject all
or part of any proposed purchase of securities. If we do offer securities through agents or underwriters, we will include in the
applicable prospectus supplement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; padding-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the name of those agents or underwriters;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">applicable fees, discounts and commissions to be paid to them;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">details regarding options to purchase additional securities, if any; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the net proceeds to us. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B><I>Common Stock.</I></B>&nbsp;&nbsp;We
may issue shares of our common stock from time to time. Holders of our common stock are entitled to one vote per share on all matters
submitted to a vote of shareholders. Subject to any preferences of any of our preferred stock that may be outstanding, holders
of our common stock are entitled to dividends when and if declared by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B><I>Warrants.</I></B>&nbsp;&nbsp;We may
issue warrants for the purchase of common stock in one or more series, from time to time. We may issue warrants independently or
together with common stock, and the warrants may be attached to or separate from our common stock. In this prospectus, we have
summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any
free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered,
as well as the complete warrant agreement and warrant certificate that contain the terms of the warrants. We will file as an exhibit
to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with
the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series
of warrants we are offering before the issuance of the related series of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We will evidence each series of warrants
by warrant certificates that we will issue. Warrants may be issued under an applicable warrant agreement that we enter into with
a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating
to the particular series of warrants being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_004"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Statements contained in this prospectus,
in the documents incorporated by reference herein and in any prospectus supplement or free writing prospectus that we may authorize
to be provided to you that are not strictly historical in nature are forward-looking statements within the meaning of Section 27A
of the Securities Act and within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act. These forward-looking statements are subject to the &ldquo;safe harbor&rdquo; created by Section 27A of the Securities Act
and Section 21E of the Exchange Act and may include, but are not limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our estimates regarding anticipated operating losses, capital requirements and needs for additional funds;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to manufacture, or otherwise secure the manufacture of, sufficient amounts of our product candidates for our preclinical studies and clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our clinical development plans, including planned clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our research and development plans, including our plans to initiate a clinical trial of AB-SA01 for the treatment of wounds infected with S. aureus in the first half of 2016;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to select combinations of phages to formulate our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the safety and efficacy of our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the anticipated regulatory pathways for our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the content and timing of submissions to and decisions made by the U.S. Food and Drug Administration and other regulatory agencies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to leverage the experience of our management team;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to attract and keep management and other key personnel;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the capacities and performance of our suppliers, manufacturers, contract research organizations and other third parties over whom we have limited control;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the actions of our competitors and success of competing drugs that are or may become available;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our expectations with respect to future growth and investments in our infrastructure, and our ability to effectively manage any such growth;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the size and potential growth of the markets for any of our product candidates, and our ability to capture share in or impact the size of those markets;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the benefits of our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">market and industry trends;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the effects of government regulation and regulatory developments, and our ability and the ability of the third parties with whom we engage to comply with applicable regulatory requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the accuracy of our estimates regarding future expenses, revenues, capital requirements and need for additional financing;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our expectations regarding future planned expenditures;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of any of our products and product candidates; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to operate our business without infringing the intellectual property rights of others. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 25; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">In some cases, you can identify forward-looking
statements by terms such as &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo;
&ldquo;goal,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;predicts,&rdquo;
&ldquo;projects,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; the negative of these words and words or
similar expressions intended to identify forward-looking statements. These statements reflect our views as of the date on which
they were made with respect to future events and are based on assumptions and subject to risks and uncertainties. The underlying
information and expectations are likely to change over time. Given these uncertainties, you should not place undue reliance on
these forward-looking statements as actual events or results may differ materially from those projected in the forward-looking
statements due to various factors, including, but not limited to, those set forth under the heading &ldquo;Risk Factors&rdquo;
in any applicable prospectus supplement or free writing prospectus and in our SEC filings. These forward-looking statements represent
our estimates and assumptions only as of the date of the document containing the applicable statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">You should rely only on the information contained,
or incorporated by reference, in this prospectus, the registration statement of which this prospectus is a part, the documents
incorporated by reference herein, and any applicable prospectus supplement or free writing prospectus and understand that our actual
future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing
documents by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking
statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time
means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase
our securities, you should carefully consider the risk factors discussed here or incorporated by reference, in addition to the
other information set forth in this prospectus, any accompanying prospectus supplement or free writing prospectus and in the documents
incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_005"></A><B>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Except as described in any prospectus supplement
or in any related free writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds
from the sale of securities under this prospectus for general corporate purposes, including manufacturing expenses, clinical trial
expenses, research and development expenses and general and administrative expenses. We may also use a portion of the net proceeds
to in-license, invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no
current plans, commitments or agreements with respect to any acquisitions. As of the date of this prospectus, we cannot specify
with certainty all of the particular uses of the proceeds from the sale of securities under this prospectus. Accordingly, we will
retain broad discretion over the use of such proceeds. Pending the use of the net proceeds from the sale of securities under this
prospectus as described above, we intend to invest the net proceeds in investment-grade, interest-bearing instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 27; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_006"></A>DESCRIPTION OF CAPITAL STOCK </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our articles of incorporation authorize us
to issue up to 670,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value
$0.01 per share. As of April 15, 2016, we had 8,242,528 shares of common stock outstanding and no shares of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The following summary description of our
capital stock is based on the provisions of our articles of incorporation and bylaws and the applicable provisions of the Washington
Business Corporation Act, or WBCA. This information is qualified entirely by reference to the applicable provisions of our articles
of incorporation, bylaws and the WBCA. For information on how to obtain copies of our articles of incorporation and bylaws, which
are exhibits to the registration statement of which this prospectus is a part, see &ldquo;Where You Can Find More Information&rdquo;
and &ldquo;Incorporation of Certain Information by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our common stock is entitled to one vote
for each share held on all matters submitted to a vote of the shareholders, including the election of directors, and does not have
cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election
of directors can elect all of the directors standing for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dividends </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Subject to preferences that may be applicable
to any then-outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared
from time to time by our board of directors out of legally available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidation </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">In the event of our liquidation, dissolution
or winding-up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution
to shareholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference
granted to the holders of any outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Rights and Preferences </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Holders of our common stock have no preemptive,
conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights,
preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the
holders of shares of any series of our preferred stock that are outstanding or that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fully Paid and Nonassessable </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">All of our outstanding shares of common stock
are, and the shares of common stock to be issued in any offering under this prospectus will be, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our board of directors has the authority,
without further action by the shareholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish
from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the
shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the
number of shares of any such series, but not below the number of shares of such series then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our board of directors may authorize the
issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the
holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions
and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control
that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting
and other rights of the holders of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">There currently are no provisions under our
amended and restated articles of incorporation or under any other contractual obligations whereby we are authorized or required
to issue or sell shares of preferred stock and we have no present plans to issue any shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Rights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Certain holders of shares of our common stock
and of warrants to purchase shares of our common stock, or their transferees, are entitled to certain registration rights under
the Securities Act as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>Demand registration rights.</I>&nbsp;&nbsp;Pursuant
to that certain Subscription Agreement, dated June 26, 2013, which we refer to as the June 2013 Subscription Agreement, from the
date that is the earlier of (a) June 26, 2018 and (b) 180 days after the effective date of the registration statement for our initial
public offering, the holders of at least 50% of our common stock issued upon conversion of shares of our Series B redeemable convertible
preferred stock and/or issued or issuable upon the exercise of warrants issued pursuant to the June 2013 Subscription Agreement
are entitled to request to have such shares registered by us on a Form S-1 registration statement. As of April 15, 2016, the holders
of an aggregate of 2,114,534 shares of common stock and holders of warrants to purchase an aggregate of 467,035 shares of our common
stock are entitled to such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>Form S-3 registration rights.</I>&nbsp;&nbsp;At
any time we are eligible to use a Form S-3 registration statement, holders of at least 30% of our common stock issued upon conversion
of shares of our Series B redeemable convertible preferred stock and/or issued or issuable upon the exercise of warrants issued
pursuant to the June 2013 Subscription Agreement are entitled to request to have such shares registered by us on a Form S-3 registration
statement. As of April 15, 2016, the holders of an aggregate of 2,114,534 shares of common stock and holders of warrants to purchase
an aggregate of 467,035 shares of our common stock are entitled to such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>&ldquo;Piggyback&rdquo; registration rights.</I>&nbsp;&nbsp;If
we propose to file a registration statement to register any of our securities under the Securities Act either for our own account
or for the account of other securityholders, the holders of warrants to purchase an aggregate of 27,102 shares of our common stock
are entitled to notice of the registration and will be entitled to include the shares of common stock issued or issuable upon exercise
of such warrants in any such registration statement. These piggyback registration rights are subject to specified conditions and
limitations, including, in the case of an underwritten offering, the right of the underwriters to limit the number of shares included
in any such registration under specified circumstances. The warrants described above in this paragraph expire in December 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">In addition, so long as we are required to
maintain an effective registration statement covering shares of common stock issued pursuant to that certain Subscription Agreement,
dated December 16, 2013, which we refer to as the December 2013 Subscription Agreement, or shares of common stock issued pursuant
to that certain Subscription Agreement, dated March 10, 2015, which we refer to as the March 2015 Subscription Agreement, then,
if there is not an effective registration statement covering such shares, the holders of such shares will be eligible for the rights
contained in the immediately preceding paragraph. With respect to each holder of the foregoing registration rights, we are required
to keep a registration statement covering such shares effective until all applicable shares of common stock held by such holder
may be sold under Rule 144 of the Securities Act. As of April 15, 2016, the holders of an aggregate of 867,241 shares of common
stock were entitled to such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">If we propose to file a registration statement
under the Securities Act with respect to an underwritten offering for our own account, the holders of the securities issued pursuant
to the June 2013 Subscription Agreement, as well as the shares held by Intrexon Corporation, will be entitled to advanced notice
of the proposed filing of such registration statement and will be entitled to include the securities described above or, in the
case of Intrexon Corporation, the shares of common stock held by Intrexon Corporation, in any such registration statement. These
piggyback registration rights are subject to specified conditions and limitations, including, in the case of an underwritten offering,
the right of the underwriters to limit the number of shares included in any such registration under specified circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">From the date that is the earlier of (a)
December 31, 2016 or (b) the closing of our first underwritten public offering, the holders of warrants to purchase an aggregate
of 170,000 shares of our common stock, which warrants were issued by us pursuant to our acquisition of certain assets of Novolytics
Limited in January 2016, will be entitled to piggyback registration rights provided such securities are not then covered by an
effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 29; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>Resale registration statements.</I>&nbsp;&nbsp;Pursuant
to that certain Registration Rights Agreement, dated December 16, 2013, by and between us and the purchasers of shares of common
stock and warrants to purchase common stock named therein, and that certain Registration Rights Agreement, dated March 10, 2015,
by and between us and the purchasers of shares of common stock and warrants to purchase common stock named therein, we agreed to
file registration statements on Form S-1 covering the resale of the shares of common stock purchased under the December 2013 Subscription
Agreement or March 2015 Subscription Agreement, as applicable, which became effective on December 29, 2014 and May 14, 2015, respectively.
With respect to each holder of the foregoing registration rights, we are required to keep such registration statements effective
until all applicable shares of common stock may be sold under Rule 144 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"><I>Expenses of registration.</I>&nbsp;&nbsp;We
will pay all expenses relating to any piggyback or Form S-1 or S-3 registration, other than underwriting discounts and commissions,
subject to specified conditions and limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Provisions of Our Articles of Incorporation,
Our Bylaws and Washington Law </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Provisions in our articles of incorporation,
our bylaws and under Washington law may delay or prevent an acquisition of us or a change in our management. These provisions include
a classified board of directors and a requirement for the vote of shareholders holding at least two-thirds of all shares of our
issued and outstanding capital stock to approve certain changes to our articles of incorporation or any business combination, such
as a merger or a share exchange with another company. In addition, these provisions may frustrate or prevent any attempts by our
shareholders to replace or remove our current management by making it difficult for shareholders to replace members of our board
of directors, which is responsible for appointing the members of our management. Additionally, because we are incorporated in Washington,
we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act, which, among other things, prohibits
a target corporation, with certain exceptions, from engaging in certain &ldquo;significant business transactions&rdquo; for a period
of five years after the share acquisition by an &ldquo;acquiring person&rdquo;, unless (a) the significant business transaction
is approved by a majority of the members of the target corporation&rsquo;s board of directors prior to the time of acquisition
or (b) the significant business transaction was approved by both the majority of the members of the target corporation&rsquo;s
board of directors and approved at a shareholder meeting by at least two-thirds of the outstanding voting shares (excluding the
acquiring person&rsquo;s shares or shares over which the acquiring person has voting control) at or subsequent to the acquiring
person&rsquo;s share acquisition. An &ldquo;acquiring person&rdquo; is defined as a person or group of persons which beneficially
owns 10% or more of the voting securities of the target corporation. Such prohibited transactions may include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any merger or consolidation with, disposition of assets to, or issuance or redemption of stock to or from, the acquiring person;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any termination of 5% or more of the employees of the target corporation as a result of the acquiring person&rsquo;s acquisition of 10% or more of the shares; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">allowing the acquiring person to receive any disproportionate benefit as a shareholder. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">After the five-year period, a significant
business transaction may take place as long as it complies with certain fair price provisions of the statute or is approved by
a majority of the votes entitled to be counted within each voting group entitled to vote separately on the transaction (excluding
the acquiring person&rsquo;s shares or shares over which the acquiring person has voting control) at an annual or special meeting
of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Articles of Incorporation and Bylaws </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The provisions of our articles of incorporation
and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management,
including transactions in which shareholders might otherwise receive a premium for their shares or transactions that our shareholders
might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common
stock. Among other things, our certificate of incorporation and bylaws would:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">provide that shareholders seeking to present proposals before a meeting of shareholders or to nominate candidates for election as directors at a meeting of shareholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a shareholder&rsquo;s notice; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt">&nbsp;</TD>
    <TD STYLE="width: 15pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose). </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NYSE MKT Listing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our common stock is listed on the NYSE MKT
under the symbol &ldquo;APHB.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The transfer agent and registrar for our
common stock is Computershare. The transfer agent and registrar&rsquo;s address is 250 Royall Street, Canton, MA 02021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_007"></A><B>DESCRIPTION OF WARRANTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We may issue warrants for the purchase of
common stock in one or more series. We may issue warrants independently or together with common stock, and the warrants may be
attached to or separate from our common stock. While the terms summarized below will apply generally to any warrants that we may
offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement.
The terms of any warrants offered under a prospectus supplement may differ from the terms described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">We have filed a form of warrant agreement
and form of warrant certificate containing the terms of the warrants being offered as an exhibit to the registration statement
of which this prospectus is a part. We will file as an exhibit to the registration statement of which this prospectus is a part,
or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, including a form of warrant
certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series
of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified
in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular
series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to
the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and
the complete warrant agreements and warrant certificates that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We will describe in the applicable prospectus
supplement the terms of the series of warrants being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the offering price and aggregate number of warrants offered;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the currency for which the warrants may be purchased;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if applicable, the number of warrants issued with each share of common stock;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if applicable, the date on and after which the warrants and the related shares will be separately transferable;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of shares of common stock purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the terms of any rights to redeem or call the warrants;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any provisions for changes to or adjustments in the exercise price or number of shares issuable upon exercise of the warrants;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the dates on which the right to exercise the warrants will commence and expire;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the manner in which the warrant agreements and warrants may be modified; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Before exercising their warrants, holders
of warrants will not have any of the rights of holders of common stock purchasable upon such exercise, including the right to receive
dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exercise of Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Each warrant will entitle the holder to purchase
the number of shares of common stock that we specify in the applicable prospectus supplement at the exercise price that we describe
in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants
may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus
supplement. After the close of business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Holders of the warrants may exercise the
warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and
paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement.
We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that
the holder of the warrant will be required to deliver to the warrant agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Upon receipt of the required payment and
the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office
indicated in the applicable prospectus supplement, we will issue and deliver the shares purchasable upon such exercise. If fewer
than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for
the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender
securities as all or part of the exercise price for warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Unless we provide otherwise in the applicable
prospectus supplement, the warrants and warrant agreements will be governed by and construed in accordance with the laws of the
State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enforceability of Rights by Holders of Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Each warrant agent will act solely as our
agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder
of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will
have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty
or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may,
without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right
to exercise, and receive the securities purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_008"></A><B>LEGAL OWNERSHIP OF SECURITIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We can issue securities in registered form
or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons
who have securities registered in their own names on the books that we or any applicable trustee, depository or warrant agent maintain
for this purpose as the &ldquo;holders&rdquo; of those securities. These persons are the legal holders of the securities. We refer
to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names,
as &ldquo;indirect holders&rdquo; of those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">As we discuss below, indirect holders are
not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Book-Entry Holders </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We may issue securities in book-entry form
only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global
securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions
that participate in the depositary&rsquo;s book-entry system. These participating institutions, which are referred to as participants,
in turn hold beneficial interests in the securities on behalf of themselves or their customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Only the person in whose name a security
is registered is recognized as the holder of that security. Securities issued in global form will be registered in the name of
the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as
the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the
payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners.
The depositary and its participants do so under agreements they have made with one another or with their customers; they are not
obligated to do so under the terms of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">As a result, investors in a book-entry security
will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other
financial institution that participates in the depositary&rsquo;s book-entry system or holds an interest through a participant.
As long as the securities are issued in global form, investors will be indirect holders, and not holders, of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Street Name Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We may terminate a global security or issue
securities in non-global form. In these cases, investors may choose to hold their securities in their own names or in &ldquo;street
name.&rdquo; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial
institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account
he or she maintains at that institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">For securities held in street name, we will
recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as
the holders of those securities, and we will make all payments on those securities to them. These institutions pass along the payments
they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements
or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders,
of those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Holders </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Our obligations, as well as the obligations
of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities.
We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect
means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are
issuing the securities only in global form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">For example, once we make a payment or give
a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements
with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Considerations for Indirect Holders </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">If you hold securities through a bank, broker
or other financial institution, either in book-entry form or in street name, you should check with your own institution to find
out:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">how it handles securities payments and notices;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether it imposes fees or charges;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">how it would handle a request for the holders&rsquo; consent, if ever required;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if the securities are in book-entry form, how the depositary&rsquo;s rules and procedures will affect these matters. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Global Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">A global security is a security that represents
one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global
securities will have the same terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Each security issued in book-entry form will
be represented by a global security that we deposit with and register in the name of a financial institution or its nominee that
we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the
applicable prospectus supplement, the Depository Trust Company, or DTC, will be the depositary for all securities issued in book-entry
form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">A global security may not be transferred
to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination
situations arise. We describe those situations below under &ldquo;Special Situations When a Global Security Will Be Terminated.&rdquo;
As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all securities
represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial
interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with
the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will
not be a holder of the security, but only an indirect holder of a beneficial interest in the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">If the prospectus supplement for a particular
security indicates that the security will be issued in global form only, then the security will be represented by a global security
at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another
book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Considerations for Global Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">As an indirect holder, an investor&rsquo;s
rights relating to a global security will be governed by the account rules of the investor&rsquo;s financial institution and of
the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of
securities and instead deal only with the depositary that holds the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">If securities are issued only in the form
of a global security, an investor should be aware of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An investor cannot cause the securities to be registered in his or her name and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The depositary&rsquo;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&rsquo;s interest in a global security. We and any applicable trustee have no responsibility for any aspect of the depositary&rsquo;s actions or for its records of ownership interests in a global security. We and the trustee also do not supervise the depositary in any way.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt">&nbsp;</TD>
    <TD STYLE="width: 15pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Financial institutions that participate in the depositary&rsquo;s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Situations When a Global Security Will Be Terminated
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">In a few special situations described below,
the global security will terminate, and interests in it will be exchanged for physical certificates representing those interests.
After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors
must consult their own banks or brokers to find out how to have their interests in securities transferred to their own name, so
that they will be direct holders. We have described the rights of holders and street name investors above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The global security will terminate when the
following special situations occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if we notify any applicable trustee that we wish to terminate that global security; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The applicable prospectus supplement may
also list additional situations for terminating a global security that would apply only to the particular series of securities
covered by the prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee,
is responsible for deciding the names of the institutions that will be the initial direct holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_009"></A>PLAN OF DISTRIBUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We may sell our securities covered by this
prospectus in any of three ways (or in any combination):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to or through underwriters or dealers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">directly to one or more purchasers; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">through agents. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We may distribute the securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">from time to time in one or more transactions at a fixed price or prices, which may be changed from time to time;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">at market prices prevailing at the time of sale;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">at prices related to the prevailing market prices; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">at negotiated prices. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Each time we offer and sell securities covered
by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution and set
forth the terms of the offering, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the name or names of any underwriters, dealers or agents;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the amounts of securities underwritten or purchased by each of them;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the purchase price of securities and the proceeds we will receive from the sale;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any option under which underwriters may purchase additional securities from us;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any underwriting discounts or commissions or agency fees and other items constituting underwriters&rsquo; or agents&rsquo; compensation;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the public offering price of the securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any discounts, commissions or concessions allowed or reallowed or paid to dealers; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any securities exchange or market on which the securities may be listed. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">Any public offering price and any discounts
or concessions allowed or reallowed or paid to dealers may be changed from time to time. We may determine the price or other terms
of the securities offered under this prospectus by use of an electronic auction. We will describe how any auction will determine
the price or any other terms, how potential investors may participate in the auction and the nature of the obligations of the underwriter,
dealer or agent in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">Underwriters or dealers may offer and sell
the offered securities from time to time in one or more transactions, including negotiated transactions, at a fixed public offering
price or at varying prices determined at the time of sale. If underwriters or dealers are used in the sale of any securities, the
securities will be acquired by the underwriters or dealers for their own account and may be resold from time to time in one or
more transactions described above. The securities may be either offered to the public through underwriting syndicates represented
by managing underwriters, or directly by underwriters or dealers. Generally, the underwriters&rsquo; or dealers&rsquo; obligations
to purchase the securities will be subject to certain conditions precedent. The underwriters or dealers will be obligated to purchase
all of the securities if they purchase any of the securities, unless otherwise specified in the prospectus supplement. We may use
underwriters with whom we have a material relationship. We will describe the nature of any such relationship in the prospectus
supplement, naming the underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">We may sell the securities through agents
from time to time. The prospectus supplement will name any agent involved in the offer or sale of the securities and any commissions
we pay to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment. We may authorize
underwriters, dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public offering
price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified
date in the future. The contracts will be subject only to those conditions set forth in the prospectus supplement, and the prospectus
supplement will set forth any commissions we pay for solicitation of these contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">Agents, dealers and underwriters may be
entitled to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, or to contribution
with respect to payments which the agents, dealers or underwriters may be required to make in respect thereof. Agents, dealers
and underwriters may be customers of, engage in transactions with, or perform services for us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">All securities we may offer, other than
common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these
securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee
the liquidity of the trading markets for any securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">Any underwriter may engage in over-allotment,
stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act.
Over-allotment involves sales in excess of the offering size, which create a short position. This short sales position may involve
either &ldquo;covered&rdquo; short sales or &ldquo;naked&rdquo; short sales. Covered short sales are short sales made in an amount
not greater than the underwriters&rsquo; over-allotment option to purchase additional securities in the relevant offering. The
underwriters may close out any covered short position either by exercising their over-allotment option or by purchasing securities
in the open market. To determine how they will close the covered short position, the underwriters will consider, among other things,
the price of securities available for purchase in the open market, as compared to the price at which they may purchase securities
through the over-allotment option. Naked short sales are short sales in excess of the over-allotment option. The underwriters must
close out any naked short position by purchasing securities in the open market. A naked short position is more likely to be created
if the underwriters are concerned that, in the open market after pricing, there may be downward pressure on the price of the securities
that could adversely affect investors who purchase securities in the offering. Stabilizing transactions permit bids to purchase
the underlying security for the purpose of fixing the price of the security so long as the stabilizing bids do not exceed a specified
maximum. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold
by the dealer are purchased in a covering transaction to cover short positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">Any underwriters who are qualified market
makers on the NYSE MKT may engage in passive market making transactions in our common stock and warrants, as applicable, on the
NYSE MKT in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the
commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations
and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess
of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&rsquo;s bid,
however, the passive market maker&rsquo;s bid must then be lowered when certain purchase limits are exceeded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">Similar to other purchase transactions,
an underwriter&rsquo;s purchase to cover the syndicate short sales or to stabilize the market price of our securities may have
the effect of raising or maintaining the market price of our securities or preventing or mitigating a decline in the market price
of our securities. As a result, the price of our securities may be higher than the price that might otherwise exist in the open
market. The imposition of a penalty bid might also have an effect on the price of the securities if it discourages resales of the
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt; text-align: justify">Neither we nor any underwriter makes any
representation or prediction as to the effect that the transactions described above may have on the price of the securities. If
such transactions are commenced, they may be discontinued without notice at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_010"></A><B>LEGAL MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The validity of the securities being offered
by this prospectus will be passed upon for us by Cooley LLP, San Diego, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="b_011"></A><B>&nbsp;EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">Ernst &amp; Young LLP, independent registered
public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year
ended December 31, 2015, as set forth in their report (which contains an explanatory paragraph describing conditions that raise
substantial doubt about the Company's ability to continue as a going concern as described in Note 2 to the consolidated financial
statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements
are incorporated by reference in reliance on Ernst &amp; Young LLP's report, given on their authority as experts in accounting
and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="b_012"></A><B>WHERE YOU CAN FIND MORE INFORMATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We are a reporting company and file annual,
quarterly and current reports, proxy statements and other information with the SEC. We have filed with the SEC a registration statement
on Form S-3 under the Securities Act with respect to the securities we are offering under this prospectus. This prospectus, which
constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement
or the exhibits which are part of the registration statement. For further information with respect to us and the securities we
are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of
the registration statement. You may read and copy any document we file with the SEC at the SEC&rsquo;s Public Reference Room at
100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the
Public Reference Room. Our SEC filings are also available at the SEC&rsquo;s website at <I>www.sec.gov</I>. We maintain a website
at <I>www.ampliphibio.com</I>. Information contained in our website does not constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">The SEC allows us to &ldquo;incorporate by
reference&rdquo; information that we file with it, which means that we can disclose important information to you by referring you
to those documents. The information incorporated by reference is an important part of this prospectus. Information in this prospectus
supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while information
that we file later with the SEC will automatically update and supersede the information in this prospectus. We also incorporate
by reference into this prospectus all documents (other than current reports or portions thereof furnished under Item 2.02 or Item
7.01 of Form 8-K and exhibits filed on such form that are related to such items and other portions of documents that are furnished,
but not filed, pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus
is a part and prior to effectiveness of the registration statement, and (ii) after the effectiveness of the registration statement
but prior to the termination of the offering of the securities covered by this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-size: 10pt">our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 30, 2016;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Current Reports on Form 8-K, filed with the SEC on January 8, 2016, January 19, 2016, March 29, 2016, April 8, 2016, April 14, 2016 and April 20, 2016; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the description of our common stock contained in our registration statement on Form 8-A, filed with the SEC on August 18, 2015, including all amendments and reports filed for the purpose of updating such description. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">We will furnish without charge to you, on
written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents.
You should direct any requests for documents by writing us at 3579 Valley Centre Drive, Suite 100, San Diego, California 92130
or telephoning us at (858) 829-0829.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify">In accordance with Rule 412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent
that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> 4,000,000 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="tv483099_img3.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>H.C. Wainwright &amp; Co.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>January 10,
2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 40; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tv483099_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv483099_img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ /P#M P$1  (1 0,1 ?_$ +P   $$ P$! 0$
M      D !P@* 0(&! ,%"P$   <! 0$               $"!08'" 0#"1
M  4# P($ @8( @<)     0(#! 41!@< $@@A,4$B$PD4%5%A,D(6"G&!D:$C
M,Q<8L=%BTB0VMC@90Z,T5"9&AG<H$0 ! @0$ P4%!08%!0     ! @, $00%
M(3$2!D$3!U%A<8$4D:&Q(C+PP>$C%=%",Q87"/%2LD,D8G*"HE/_V@ , P$
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MJ[& CG$F[29I&,4BK@[=L8" )@ 34ZZC=!2N5=6*89J,HCE!2NU=6*89J,H
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MG3K(U#Z3@1+ 07OW$TR?VB98\H=6,57]<RUK^CMJG>G2$4^\J9# TI5.8''
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M^';KV]O=B^<VW52.4I29@\#PEY1T[?WFS?%N4-4@-%0F.P^^+87LL<HR<HN
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M&@]=33H[3LU#=>75A!13H([S.,5=?VDN)M[CA(IUU"D3 )QTDRD)G+CE$^.
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M&^!B0VE*81K\X:C3H'<-51T[6E[>%,ZV?RT3F<N![8NGJLL4^R*AEV?,61(
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..\]*]4YXQYZ5:ISQC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tv483099_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv483099_img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ +0"H P$1  (1 0,1 ?_$ +(   $#!0$!
M      D !PH! @0&" 4# 0 !! ,! 0               P4&!P($" $)$
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M1U?_ #JQ,>[& .YZ!UI(2QZA,N<^F)GIN@=.@[_[0UQB $C# :H^@RN?^,Q
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M" ]!#6(26R%,G2H1XI*'4%NH2%H/ QPKR X%XGRNS3F:2P@L491B%IQ]6;_
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/T?'7ATZ,)Z8\5*7&4?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tv483099_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv483099_img3.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 6P%4 P$1  (1 0,1 ?_$ .   0 " @,  P$
M       )"@<(!08+ 0($ P$!  (# 0$! 0            8'! 4( P(!"1
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M*OD" L*"]_;4K(%F-64Z7D9;'[Q<CLE<]QF7,JD::BF:[YB"Z)15;HB @!Q
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M976ZO2SJ-IV,X#+F/6M2Q%06*58QU5X]K/LB,F;*"CRHHNQ:) !2J./.)?X
M$#PYDU.W[;9K#6KITE=6JF<U.K[3BCI,\3EY!+SQQZWO?<6[MXT#UV?46#7M
M$-))" =8Q.,UJ^<LD]$HMC<Y\CK.'$(J%_BM=P@JV*,-:4U66 DSE.6_2WE)
MJW4 %4:%3W2C&F1;L2&$01L-P]9R*9@#J$24?$!#EG>'%KYE2[=G!V6QH1Z2
MOC'S)P_6BW?"JS\VK>O;H[#0Y:#\Y6*CYDX?K1T3\.1VK\#95U;ONS6T^$*/
ME@V6[J,%B2,R-76TZTA:-1/>&$I88AJ_3.BBI:;2Z<)&6*'F,C&D !\IAZ^V
M^MQ5E-<46^W/+:Y2)K*3*:E8@'R#X8]_$;=-?2W1NV6M];7)1-PH,IJ7B 9?
M)3+\L6)_^$[VU?\ ](=<?_MK _\ N_(-_B6__P"UO_SC%=_XKW+_ +=4_P \
MQ2"_$6Z"TW33;>IW3#%(BZ!@S/U(1E:[7ZM'A%UJK7ZF>[PUQ@XEL@4K=B+Q
MHHQE2II]  [M02@'0>EN;&O+MUMBFJI976,KD23,E*L4D_G'FB[_  [O[UYM
M"V:Q9<KJ=<E%1FI2%8I)Z>*?,(N4=E?<0=TNWSA:_34J62R30HTV'LK"90IG
M8W+'Z#:-3E7@=14%6RUP["1,<P!YU'1_;T'E6;LM?LF]NLH$J=9UH]%6,O,9
MCS13>];/[%W ]3H$J9P\QOT5XR_5,T^:(7_Q=/ZE=*OVNY2^PT/R5^&7[U5_
M9([QB:>$?[Y7?9-]XQO%^&%_JM8#]NF8O_;X;FG\0?>)7V+?P&-%XG>]*OL&
M_@,;8/>REHJ_W@2WU6I=@#*J=H0OJE,3F&9<2.<AMVGHIWIQ3?A(J'GQ?@61
M-_?0-SR107%(3=0'7#=EX3:/8P6GU?3IU2[>GY.J>4L,IRPC5)WK?4V/V"%I
M]5TZ-4OI-'R=4\I893EA.(YOQ7?W"<0?[SE5^PU\YO/#?\:=^[J[R8D7A3^/
M/?=5=Y$<5^$Y^XYGC_>=FOZ.J%S[\2?Q9C[N.^J/OQ7_ !RG^ZCOKBSG=?YF
MVWZLSW\E.^5\U]:GTA\,5DS]<CTA\,>7QV7*)2<E]U?7"DY%J-;O=-F[EDQ.
M9JEOA8^PUV6(THEW>M224-*MW4>](W>MTU2 HF8"J$*;IU .=";K>>I]N5#K
M"E(="$2*201VDY$8QT]O-]^FVI4O4ZU-O);1)2201VDC C$81Z<6.\,8?Q"T
M488IQ9CO&K-8H$6;T.EUVII+D*/4I7!8*.8^N #[//YNG.?WZNJJCJJ7''#\
MY15\)CF6HK:RL.JK=<=/SE%7PDQDOF/&-$!7XEO^JDRA^T[#/VW9<FFP/>1O
M[-SNQ/O#3WK:^R<[IBO+^'=[D^H&@=4VGC=HLD2%#?9,M&,)*FHLJ9;+4$FR
MK<-:F<PJHI68F4(R,V<2:( 5;R"<#=2]>@\F^^+#=+TY3*MS86&TK"NTD2F1
M+,CHBPO$/;=WO[M*JUMAQ+25A4U)3(DI(^,1/(Y1:BP-WP^V]LMEZC8+P_FN
M8LF2\CRJD+4H-QC/(<,C(R"3%W)*(J2DM7&<<S*#1DH;S*JD+]'IUZB'*ZK-
MH7Z@I5UE4T$T[8FHZTF0RR!G%6U^Q]R6VC<KZME*:9H34=:#(3ED#,XF);>1
MF(C'EH84_KPJ7_S+7O\ 3[*<Z)J_=%?]W_LQ'4=;[D+_ +L']D(]2_G.T<N1
M"1WKOU>8)^N]K^S[+EI>%_[Y5_9([QBB_''\.M_V[G<$=V[,OW?LA_M4=_9R
M#YB^)GXNQ]W'>5&=X)>[U5]\/<1$P/*WBYH<0C2+N-_<QS?_ )"B?M-"\E6R
M?>>E])7<5$$\3/<BO^S3_:(B,#LH_K#SO]3:?_+<KR>>*'[A2?:K[HBJO [\
M4N'W=OOJBPYRF8Z0BJ'W6OOBWKZJ4G[/(\Z#\/\ W:9^T<[T<B^+7OK4_8M?
MV8BT#B[]66.OJ)4?L_'\H>O_ 'Y_[9?>,=56G\*ION[?<$1[=WG[HBG[4*+_
M )WY,O#CWB_AW/Z,5QXR^YW\6S_2BO-_LS?Z>O\ 5WRX_P#?G\)^TCG/_EC_
M (A^QBZ[SE^.XX<0C7+8#5/">RL,,=DRI-G$L@B9*)N,2"<9<(01_-]QFDTC
M*JMRCXBW< LV-^4G7QYN[/N"Z6-W70N$-DXH.*%>5/3UB1ZXC.XMHV/=#'+N
MC(+P'9<3V7$^171U&:>J*\NT';)S7@CXA9J2BXRYC=N*JYI.!8F^:X-H F$H
MS];0%5==-),/IN67JI![3E3Y<EAWS:[OI8J2*:N.$E'L*/S5</(J1Z"8YRW5
MX77W;^JJH0:RV#'4@?2('ST9GK4F8XD".B=M0!#<S%A3 )3$0N9#E, E,0Y:
ME, 8ABCT$IBB'00'Q >9>]_=BI_4[XC!\+O?FB\J^X8I+R-4M%ZR[8J?2*W/
M7"VV#(-ICX*L5>)?3L_,/E[)(D2:QL3&(.7KM8YA]A"#T]H] YNPXVS3)=>4
ME#24 DDR $AF3']ATNM,4B7GU)0TEM)*E$  :1F3A%@'6WL60F-8:%R]W1LE
M+85K[Q!&4K^K6.'\?-[ W=$0371;69XS4>QN/HYV0WE5 !4<I^)#K-E Z<B[
MFX:RZ.&DVNSSB#)3ZP0RCR3^.1_T!$43XB>/FV-G,*:I'$NUI!TX3)/S&\"K
MTE:4=9B3&>VA94W'H8&U$QE6M3M?VP"B:JXZ3!K<;>'IF1-(W^\)C\:G))VD
M8?6,*PG4 W1114 #F=;]JT[3XK[NXJMN?RE_$3U(1D .$_,!'!6^O&/=F]:A
M>MYQBB5,2"CS%#H4H2TI^8@)3TSC4<1$1,81$3&,)C&$1$QC&'J8QC#U$QC"
M/41'Q$>2J*DC/NJ?WG-?OVP4+[0,N:B__@59]V<[IB0;2]Z+=]]9[XBZGSF&
M.X(<0B#W<_L(:E;VY]M6Q>;LF;%_.UHC8.%+'5B[56,K->@Z['$CXR(KT<]H
MTFX9,DQ]1<X'74,=PNH<1ZFZ<E]JWG<K/1)H:1MCE)),RDDDDS))U#_LB;V;
M?MVL5 BW4+5-R$DF:DJ*B29DDA8QX99 1+5@G"U%USPWC3!6,V"T;0L4TZ$I
M58;.5$UGIHV$:$;%>2+A))NFYE)%8IW#I4"$!5PJ<_E#S=.1FLJWJZJ<K*@S
M><65'RGHZAD.J(G7UK]QK':^J,ZAU94KRG@.H9#JC+',:,2-#>X#VZ]?^Y%B
MVKXKSX-NCXZF7)"[UBQ4.5CX2TQ,H2.>1+UJW?R41-M?ADLP>B1RD* B<4TQ
M P"0.;FR7VML-0JIHM)4M&DA0)!$YY C$'+&-]M_<5PVW5+JJ#05+1I4%@E)
M$P1@",01AC'1NW?VN<'=M!EDV'P->\Q3]>RH\@96?KV2K+ S\4QFZ^W>,V\U
M")157@%6,@\8.P0<B)U"JIHI=2@) 'GM?-Q5E_+:JQ#25M@@% (,CP,R<)XC
MSQ[[AW17;E4TNO;92XT" 4)()!QD9J. .(\IC]_<5[8N!>YE6,853.]CR778
M[$]CG[-75<;3D-".G3^Q13:'>IRJDQ7Y\CALFV:E%,J94Q XB(B(>'/RQ;AK
M-ON..4:6U*=2 =8)R,\)$1^;<W17[9===H4-+4\D).L$R"3,2D1&5-$](<4]
MOK K37C#4S=9VE,[99;@D_OTG&R]@&2M"K5:01.\BHB$:"S3.U+Z1?0\Q0$>
MIAYC7F[U-[K37500ETI"9)! D,LR8Q+]?*K<%P-QK$H2\4)3) ($DY9DG\\;
MD<U4::-#^X)V]L,]Q_$E;PUF^>O]?J]7O3#(#!UCN7B8:85F8Z)EH=!!TYEX
M.>;G8"VF53&(5(IQ.4H^8  0'<V2]U5AJE5=(E"G%(*>T"1(D'@1CA&^V]N&
MLVW6*K:)+:G5-E!"P2)$@\",<(_AV]^W=A7MMXKMN(L'3V0;!6[C>G.09-UD
M68B9J61F74+$0:B#-Q$0<"@FP!I#)& ADCG XF'S=!  _;Y?:N_5**FK2A*T
M(TC2"!*9/$G'&/W<.XJS<E6BLK4MI<0WH 0"!*9/$G'&-Z92/1EHR1BG!E"-
MY-B[CUSI"!52HO6ZC94R1C%,4JA2*")1$! !_)S3)44J"AF#.-$E10H*&8,X
M@PU/_#X:9Z>['4+9W&=[S[*WW'DI/RT+'6ZW521K3AQ8H67@WQ)!BPI$6\62
M(TF53)@1PF)3@41$0 0&8W+>]TNE NW5"& RL $I"@<"#A-1'#HB=7;Q"O%X
MMKEKJ6Z=+#@ )2E05@01*:B.'1$[O(;$#AQ"-1-X-,<7[\:_3NN.8)>XP=(L
M,[6; ]D*))1T58B/*K*)RT>FW>RD5--"-U7*0 J H&$Q/ ! ?'FTL]VJ++7)
MKZ4(4\E)$E D8B1R(^&-O8[U56"X)N5&E"GTI4)*!(DH2.1!_/$)7_\ *9V\
M_P#ZF;2?^O:1_P#CCDM_S(O?^JIOYJOZ\3C_ #6W!_J:3^:O^O&?M6OP[&E.
MI&P&,=CL<7W8.4N^*9U:P5Z/M=PJ<A773Q>,?Q1TY1FQHT8[70!O('$ 372'
MS  ]>G@.%<=]7:Y43E ^VP&74R)2E0,I@X34>CHC7W3Q%O5VM[MMJ&J9+#R9
M$I2H&4P<)K(X=$3Y<A<0"($JO^'>TLJ6T\7MQ'7W8)7)$3G!7/C>,=W"I*50
M]P6MZ]T,R5CB49-\:""4<&("0.05]'H'J>;Z7)HYOFZNVXVQ3;'(+/+GI5JT
MZ=,YZI3EU1/G?$2\NVHVA3=/ZL6.5,)5JTZ=,YZI3EU1/;R%Q 8U?V=U,QOM
M?#U2$R/(VJ/:4^4D):,-5I)E'+*N9)HDR7*\.\C9(JJ14D@$H% H@;\H\WUB
MW#6[><<=HDMJ4ZD ZP3@#/"1$13=6S[9NYEEBY+>2AA:E)Y9 F5"1G-*HY/6
MG6*@:L5"9I>/']ED(J<GU+$[5M#]I(/"/E&35B8B"K./CB%;^BT*/E$AA\PC
MX_DYYWR^UE_J4U58$)<0C2-(($ID\2<<8]=K[5MVTZ-RAMJG5-..:R7""9R
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MM$VUD)^,DDF%>68@9VJ"?ID*L3Z7B/246K:[]UHA7)?8:0I[E)"R05+D" )
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M@]$:RW[8N%=>UV%PI8K6PLJUSD- F<1/,8@Y2QCD=+.XUC3<JY9:Q(EC',F
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MIF*6W?/G<'6X9%TJFW,Z4$RARI 3S?QGI_MR>H[9MM-A;?;J*QQ_FK+9U(0
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M272STE11K;:#14E=,D@!*B?K$C,A7$F<L.N-1N>X45XL=%4T*VF T5(72)(
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-AQ"'$(<0AQ"'$(__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
